Clinical Trial Update: TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TAB008 to Avastin in EGFR wild-type non-squamous non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• TAB008

Snippet

Sponsor: BioDlink Biopharm Co., Ltd. | Conditions: Efficacy | Phase 3 | Status: COMPLETED